Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | CD40 | P25942 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 4/20 | 0.33 |
| ▸ | CCKBR | P32239 | 4/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922793 | 1.00 | GLP1R (0.47) | GLP1RCD40NOD1TLR2GNAI3 | |
| SCHEMBL17922809 | 0.93 | GLP1R (0.48) | GLP1RCD40NOD1TLR2CCKAR | |
| SCHEMBL16493197 | 0.93 | GLP1R (0.48) | GLP1RCD40NOD1TLR2CCKAR | |
| SCHEMBL17922798 | 0.90 | GLP1R (0.53) | GLP1RCD40NOD1TLR2CCKAR | |
| SCHEMBL17922808 | 0.90 | GLP1R (0.53) | GLP1RCD40NOD1TLR2CCKAR | |
| SCHEMBL17922797 | 0.89 | GLP1R (0.48) | GLP1RCD40NOD1TLR2GNAI3 | |
| SCHEMBL17922807 | 0.88 | GLP1R (0.47) | GLP1RCD40NOD1TLR2GNAI3 | |
| SCHEMBL16493107 | 0.88 | GLP1R (0.51) | GLP1RTLR2CCKARCCKBR | |
| SCHEMBL17922792 | 0.86 | GLP1R (0.46) | GLP1RCD40NOD1TLR2GNAI3 | |
| SCHEMBL16493127 | 0.85 | GLP1R (0.56) | GLP1RNOD1TLR2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200791-A1 | GLP-1 Derivatives, and Uses Thereof | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| WO-2015022400-A1 | GLP-1 DERIVATIVES, AND USES THEREOF | NOVO NORDISK A/S (DK) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200791-A1 | GLP-1 Derivatives, and Uses Thereof | GLP1R, IAPP, GCG | GLP1R 1/4885CD40 3396/4885NOD1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.